←
Rob Gereau2,764 posts
Rob Gereau avatar

Rob Gereau

@robgereau

Neuroscientist studying chronic pain. Vice Chair for Research at @WUSTL_AnesRsrch and Director of @WashUPain Center. Cofounder of @NeuroLuxInc

◷ Joined November 2011▧ 181 Photos and videos
Rob Gereau avatar
Rob Gereau@robgereau·11 Dec 2025

Very happy to be launching another year of ASSURE. The summer program itself is great, but the ongoing mentoring relationships with our past fellows and seeing their careers taking shape is the absolute best. Here are some brief comments from some program alumni.

Curious what the Anesthesiology Summer Research (ASSURE) Fellowship is all about? Hear directly from fellows about their summer research experience & apply now for Summer 2026! youtube.com/watch?v=YXS5XIvx…

Post attachment
Rob Gereau avatar
Rob Gereau@robgereau·3 Nov 2025

For students who have not been able to participate in research previously, this is a great opportunity to gain critical experience and mentoring in biomedical research. That experience can open doors - just ask our program alumni.

Applications are OPEN for the 2026 Anesthesiology Summer Research (ASSURE) Fellowship! #STL metro undergrads & recent grads spend the summer doing hands-on research, clinical shadowing & professional development — no experience required. assure.wustl.edu

Post attachment
WashU Medicine Anesthesiology Research avatar
⟳ Rob Gereau retweeted
WashU Medicine Anesthesiology Research@WashUAnesRsrch·25 Jul 2025

Drs. Burel Goodin (@PainBurel) & Simon Haroutounian (@S_Haroutounian) have been selected for the 2025 cohort of the Mayday Pain & Society Fellowship! Congratulations to these two extraordinary #WashUanesthesiology faculty members! anesthesiology.wustl.edu/two…

Rob Gereau avatar
Rob Gereau@robgereau·5 Mar 2025

We acknowledge and greatly appreciate support from the National Institutes of Health for funding not only this work but also decades of foundational forming the knowledge base that enabled these recent advances. Without NIH funding this wouldn't have happened

Rob Gereau avatar
Rob Gereau@robgereau·5 Mar 2025

This new class of agonists shows signaling bias, substantially improved peripheral restriction compared to previously reported "peripherally-restricted" CB1 ligands. The result is a dramatic reduction in analgesic tolerance and unwanted CNS-mediated side effects.